# Postmarket Safety Actions for Novel Oncology Drugs Granted FDA’s Accelerated Approval

## TL;DR

This study analyzes safety actions taken after FDA's fast-tracked approval of new cancer drugs.

## Contribution

It provides insights into postmarket safety measures for oncology drugs with accelerated approval.

## Key findings

- Postmarket safety actions were frequently required for these drugs.
- Some drugs faced restrictions or warnings due to safety concerns.
- The study highlights the importance of continued monitoring after accelerated approval.

## Abstract

This cross-sectional study examines postmarket safety actions for novel oncology drugs that received accelerated Food and Drug Administration (FDA) approval.